Lisdexamfetamine Dimesylate (LDX)
SPD489-115
Phase 1 small_molecule completed
Quick answer
Lisdexamfetamine Dimesylate (LDX) for Attention-Deficit Hyperactivity Disorder is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention-Deficit Hyperactivity Disorder
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed